关于心血管疾病的错误信息通过社交网络传播:一个范围审查协议
Buna Bhandari1,2, Jessica Hanae Zafra-Tanaka3,4,5, Pranab Mahapatra3,6
1Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA buna.bhandari@gmail.com.
BMJ open
|July 16, 2025
概括
本范围审查绘制了心血管健康错误信息的地图,详细说明了其传播,流行,影响和纠正策略. 它解决了理解错误信息如何影响公共卫生结果的关键差距.
科学领域:
- 公共卫生 公共卫生
- 心血管医学 心血管医学
- 卫生沟通健康沟通
背景情况:
- 关于心血管健康的错误信息对公众健康构成重大风险.
- 对心血管健康错误信息的全面理解对于开发有效干预措施至关重要.
- 缺乏关于心血管健康错误信息的现有文献评论.
研究的目的:
- 绘制有关心血管健康错误信息的现有文献.
- 确定心血管健康错误信息的传播,流行和影响.
- 探索各种人群中纠正心血管健康错误信息的策略.
主要方法:
- 这项研究采用了根据乔安娜·布里格斯研究所指导方针的范围审查方法.
- 在多个数据库 (MEDLINE,EMBASE,SCOPUS,Web of Science) 和灰色文献中进行了全面的搜索.
- 数据提取和描述性分析是由两个独立的审稿人使用Covidence软件进行的.
主要成果:
- 该审查综合了关于心血管错误信息的特征,传播模式和公共卫生影响的发现.
- 确定了用于纠正错误信息和促进准确的心血管健康信息的各种策略.
- 该分析捕捉了影响错误信息的各种文化,地理和特定环境因素.
结论:
- 本综述提供了关于心血管健康错误信息的当前情景的全面概述.
- 调查结果强调需要有针对性的干预措施和公共卫生战略来打击错误信息.
- 结果的传播将为公共卫生组织,政策制定者和未来的研究工作提供信息.
相关概念视频
01:23Assessment of the Cardiovascular System I: Subjective Data
470
A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
470
01:29Bias in Epidemiological Studies
695
Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:
695
01:26Coronary Artery Disease IV: Preventive Measures
38
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
38
01:30Coronary Artery Disease I: Introduction
60
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
60
01:26Coronary Artery Disease II: Pathophysiology
40
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
40
01:26Atherosclerosis III: Management
40
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
40